GenBook White Paper

Introduction

In the technological wave of the 21st century, the integration of biotechnology and blockchain technology is giving birth to a new revolution. As a pioneer of this revolution, GenBook came into being, dedicated to pushing the transaction and sharing of genetic data to a new level.

Genes, as the code of life, carry the genetic information of organisms. With the rapid development of biotechnology, the importance of genetic data has become increasingly prominent, and its application prospects in disease diagnosis, drug development, personalized medicine and other fields are broad. However, the transaction and sharing of genetic data face many challenges, such as data privacy protection, transaction credibility, and equity distribution. The traditional centralized data transaction model can no longer meet the needs of modern society. We need a more secure, transparent and traceable transaction mechanism to promote the development of genetic data.

The emergence of blockchain technology provides us with a solution. With its decentralized, transparent and tamper-proof characteristics, blockchain provides a new solution for trusted data transactions and value transfer. On the GenBook platform, we use blockchain technology to build a secure, transparent and traceable genetic data transaction environment. Through the automatic execution of smart contracts and the protection of encryption technology, we ensure the security and credibility of genetic data transactions, protect data privacy, and improve transaction efficiency.

GenBook 's mission is to promote the safe, transparent trading and sharing of genetic data, and to promote continuous innovation and development in the field of biotechnology. We firmly believe that genetic data will release huge value potential through the empowerment of blockchain technology and make greater contributions to human health and well-being. Our vision is to become the world's leading genetic data trading and sharing platform, providing safe, efficient and convenient genetic data trading services to global researchers, medical institutions, biotechnology companies, etc.

In order to realize this vision, we have brought together a team of consultants composed of experts in biotechnology, blockchain technology, financial investment and other fields to provide valuable strategic guidance and technical support for the project. At the same time, we have a strong technical team and rich R&D experience, and are committed to continuously innovating and improving platform functions and enhancing user experience.

Looking ahead, GenBook will work with global partners to explore the infinite possibilities of biotechnology and blockchain technology. We will continue to invest in research and development, optimize platform performance, expand application scenarios, and promote the normalization, standardization and internationalization of genetic data transactions and sharing. We believe that through cross-border cooperation and exchanges, we can gather global wisdom, jointly respond to challenges, and achieve common development.

Table of contents

1. Industry status and challenges

1.1 Shortcomings of the Current Biotechnology Industry

1.1.1 Data security and privacy protection issues

Data leakage risk: The biotechnology industry involves a large amount of sensitive personal health information, including genetic data, disease history, etc. Traditional data storage methods have the risk of leakage, which may lead to the violation of personal privacy.

Inadequate data security: Many biotech companies may lack adequate security measures to protect this data, leaving them at risk of being hacked and having their data stolen.

1.1.2 Bottlenecks in scientific research collaboration and data sharing

Cooperation barriers: Scientific research cooperation in the field of biotechnology usually requires cross-regional, cross-institutional and even cross-border cooperation. However, due to complex issues such as data ownership, intellectual property rights, and cooperation agreements, such cooperation often faces many obstacles.

Difficulty in data sharing: It is often difficult for researchers to obtain data from other research teams, which limits the progress and efficiency of scientific research. At the same time, data sharing may also be restricted by laws, ethics and privacy.

1.1.3 Challenges of authenticity and credibility of clinical trial data

Data quality issues: The authenticity and credibility of clinical trial data are key to drug development and treatment improvement. However, data quality may be compromised due to improper behavior during data collection, organization, and analysis, such as data tampering and falsification.

Insufficient supervision: Insufficient supervision of clinical trial data may also lead to problems with data authenticity and credibility. The lack of an effective supervision mechanism makes it difficult to ensure the integrity and accuracy of the data.

The current biotechnology industry is facing challenges in data security and privacy protection, scientific research cooperation and data sharing, and the authenticity and credibility of clinical trial data. Solving these problems is crucial to promoting the healthy development of the biotechnology industry.

1.2 The application potential of blockchain technology in the field of biotechnology

1.2.1 Solve data security and privacy protection issues

Blockchain technology, with its decentralization, distributed ledger and encryption mechanism, provides innovative solutions for data security and privacy protection in the biotechnology field. Through blockchain, personal health information can be safely stored in multiple copies to ensure that the data is not tampered with or leaked. At the same time, encryption technology and access control mechanisms can ensure that only authorized users can access specific data, effectively protecting personal privacy.

1.2.2 Promote scientific research collaboration and data sharing

Blockchain technology can simplify the process of scientific research cooperation and data sharing in the field of biotechnology. Through smart contracts and automatic execution mechanisms, cooperation agreements can be executed more efficiently and transparently. In addition, the distributed nature of blockchain allows data to be shared globally, breaking geographical and institutional restrictions and promoting global scientific research cooperation.

1.2.3 Improving the authenticity and credibility of clinical trial data

Blockchain technology can ensure the authenticity and credibility of clinical trial data. By storing data on the blockchain, the data can be immutable and prevented from being tampered with or falsified. At the same time, the transparency of the blockchain can be used to monitor the data collection and processing process in real time to ensure the integrity and accuracy of the data. In addition, smart contracts can also automatically verify the compliance and authenticity of data, improving the quality and credibility of clinical trial data.

Blockchain technology has great application potential in the field of biotechnology. By solving data security and privacy protection issues, promoting scientific research cooperation and data sharing, and improving the authenticity and credibility of clinical trial data, blockchain technology is expected to provide strong support for the healthy development of the biotechnology industry.

2. Project Overview

2.1 Project Introduction

2.1.1 About GenBook

GenBook is an innovative biotech data sharing and cooperation platform. Its core is to use the advantages of blockchain technology to solve the challenges faced by the biotech field, such as data security and privacy protection, scientific research cooperation and data sharing, and the authenticity and credibility of clinical trial data. The project aims to build a safe, transparent and efficient global biotech data sharing and cooperation ecosystem to promote the development of scientific research progress, drug development, personalized medicine and other fields.

2.1.2 GenBook’ s Vision

GenBook 's vision is to become the world's leading biotechnology data sharing and cooperation platform, providing safe and efficient data storage, sharing and cooperation services for researchers, medical institutions, biotechnology companies, etc. Its mission is to promote the sustainable development and innovation of the biotechnology industry by integrating blockchain technology with the actual needs of the biotechnology field, and to make positive contributions to human health and well-being.

2.2 Project background and necessity

2.2.1Project background

In the 21st century, the field of biotechnology has ushered in unprecedented development opportunities, especially significant breakthroughs have been made in gene editing, precision medicine and personalized treatment. However, with the rapid development of biotechnology, a large amount of personal genetic information and medical data are also generated. These data not only have extremely high scientific research and commercial value, and are of great significance in promoting the advancement of medical technology and improving human health, but they also bring about a series of complex problems and challenges.

On the one hand, data security and privacy protection have become urgent issues to be resolved. Personal genetic information and medical data are highly sensitive information. Once leaked or abused, it will cause serious infringement of personal privacy and may even threaten personal life safety. Therefore, how to ensure data security and privacy protection has become an important issue to be resolved in the field of biotechnology.

On the other hand, scientific research cooperation and data sharing also face many obstacles. Scientific research cooperation in the field of biotechnology usually requires cross-regional, cross-institutional and even cross-border cooperation, but due to complex issues such as data ownership, intellectual property rights, and cooperation agreements, such cooperation often faces many obstacles. At the same time, data sharing also has many difficulties, which limits the progress and efficiency of scientific research.

In addition, the authenticity and credibility of clinical trial data are also important issues facing the biotechnology field. Clinical trial data is an important basis for drug development and treatment method improvement. However, due to improper behavior in the process of data collection, collation and analysis, such as data tampering and falsification, data quality may be damaged, which in turn affects the effectiveness of drug development and treatment methods.

2.2.2Necessity of the project

In order to solve the above problems and challenges, we proposed the GenBook project. By integrating blockchain technology with the actual needs of the biotechnology field, we aim to create a secure, transparent and efficient global biotechnology data sharing and cooperation ecosystem.

First, the decentralization, distributed ledger and encryption mechanism of blockchain technology provide innovative solutions for data security and privacy protection. Through blockchain technology, we can ensure the safe storage and transmission of personal genetic information and medical data, and prevent data from being tampered with or leaked. At the same time, by using encryption technology and access control mechanisms, we can ensure that only authorized users can access specific data, effectively protecting personal privacy.

Secondly, blockchain technology can promote scientific research cooperation and data sharing. Through smart contracts and automatic execution mechanisms, we can simplify the execution process of cooperation agreements and lower the threshold for cooperation. At the same time, the distributed nature of blockchain allows data to be shared globally, breaking geographical and institutional restrictions and promoting global biotechnology cooperation and exchanges.

Finally, blockchain technology can also improve the authenticity and credibility of clinical trial data. By storing data on the blockchain, we can ensure that the data is immutable and prevent it from being tampered with or falsified. At the same time, using the transparency of the blockchain, we can monitor the data collection and processing process in real time to ensure the integrity and accuracy of the data. This will help improve the effectiveness of drug development and treatment methods

and promote the sustainable development of the biotechnology field.

GenBook project has important background and significance. By integrating blockchain technology with the actual needs of the biotechnology field, we are expected to solve problems such as data security and privacy protection, scientific research cooperation and data sharing, and the authenticity and credibility of clinical trial data, and promote the sustainable development and innovation of the biotechnology field.

2.3 Project positioning and characteristics

2.3.1 Project Positioning

GenBook project is based in the field of biotechnology and is committed to building a world-leading biotechnology data sharing and cooperation platform. Our core goal is to provide safe and efficient data storage, sharing and cooperation services for scientific researchers, medical institutions, biotechnology companies, etc. By integrating blockchain technology with the actual needs of biotechnology, we aim to promote the sustainable development and innovation of the biotechnology industry and provide strong support for scientific research cooperation and exchanges around the world.

2.3.2 Project Features

Security : We know that data security is a top priority in the biotechnology field. Therefore, the GenBook project uses the encryption mechanism and distributed ledger characteristics of blockchain technology to ensure the security of personal genetic information and medical data. Through advanced encryption algorithms and strict data access control mechanisms, we prevent data from being tampered with, leaked or abused, providing users with reliable data security protection.

Transparency : On the GenBook platform, all data is open and transparent. This means that researchers, medical institutions and enterprises can easily view and verify the source, processing and results of data. This transparency not only enhances the fairness of scientific research cooperation and data sharing, but also helps to establish a trust mechanism and promote cooperation and communication on a global scale.

Efficiency : We have greatly simplified the process of data sharing and cooperation by introducing smart contracts and automated execution mechanisms. Smart contracts can automatically execute tasks such as cooperation agreements and verify data compliance, thereby improving cooperation efficiency. In addition, we have optimized platform performance to ensure that users can access and use data quickly and accurately.

Globality : GenBook is a global platform without geographical restrictions. We welcome researchers, medical institutions and enterprises from all over the world to join our ecosystem and jointly promote the progress of biotechnology. By breaking geographical and institutional restrictions, we promote global cooperation and exchanges and accelerate the transformation and application of scientific research results.

Personalization : On the GenBook platform, we support the development and application of personalized gene editing treatment plans. This means that doctors and researchers can develop personalized treatment plans based on the patient's specific condition and needs. We provide rich data resources and efficient cooperation mechanisms to help researchers quickly find suitable partners and data resources, thereby accelerating the development and application of personalized treatment plans.

3. GenBook technical foundation

3.1 Overview of blockchain technology

Blockchain is a decentralized, trustless distributed database. It uses cryptography to ensure data security and immutability, and uses technologies such as timestamps and hash algorithms to ensure data integrity and dynamic consistency. In blockchain, data is connected in chronological order in the form of blocks, forming an immutable data chain. This technology provides a new solution for data sharing, cooperation and verification.

3.1.1 Distributed Ledger Technology

Distributed ledger technology is one of the core technologies of blockchain. Unlike traditional centralized ledgers, distributed ledgers are maintained by multiple parties, and each party has a complete copy of the ledger. This decentralized storage method ensures the reliability and security of data. Even if some nodes are attacked or fail, it will not affect the normal operation of the entire system.

3.1.2 Smart Contracts and Automatic Execution

Smart contracts are an important application of blockchain technology. They are self-executing computer programs that can automatically execute contract terms according to preset conditions. In the GenBook project, smart contracts can be used to automate data sharing, cooperation and verification processes, improve cooperation efficiency and ensure data compliance.

3.1.3 Data encryption and security

In the GenBook project, we use advanced encryption technology to ensure data security. By encrypting the data, we can prevent the data from being stolen or tampered with during transmission and storage. At the same time, we also use a variety of security mechanisms, such as identity authentication, access control, etc., to ensure that only authorized users can access and use the data.

GenBook project uses the advantages of blockchain technology and combines it with the actual needs of the biotechnology field to build a secure, transparent and efficient biotechnology data sharing and cooperation platform. Through distributed ledger technology, smart contracts and automatic execution, as well as data encryption and security measures, we provide users with reliable data security and promote scientific research cooperation and exchanges around the world.

3.2 Overview of Gene Editing Technology

GenBook 's gene editing technology is a revolutionary tool that allows researchers to modify the genome of an organism with extreme precision. This technology directly changes the DNA sequence of an organism, thereby controlling life processes at the molecular level.

3.2.1 Definition and Principle:

Gene editing technology, especially the CRISPR-Cas9 system, is a means of artificially intervening and adjusting the genome of an organism. Its core principle is to use a specific enzyme system, the CRISPR-Cas9 complex, to modify and edit specific DNA sequences in the genome. The CRISPR-Cas9 system recognizes and binds to the target DNA sequence through RNA molecules (called guide RNA or gRNA), and then the Cas9 protein cuts the DNA sequence, causing double-strand breaks in the DNA. The cell then repairs the broken DNA through repair mechanisms (such as non-homologous end joining or homologous recombination), thereby achieving genome editing.

3.2.2 Introduction to CRISPR-Cas9 technology:

CRISPR-Cas9 is one of the most commonly used technologies in the field of gene editing. It is derived from the natural defense mechanism of bacteria and can recognize and cut foreign DNA. In gene editing, researchers design specific gRNAs so that they can recognize and bind to the target DNA sequence. Once bound, the Cas9 protein cuts the DNA, causing double-strand breaks in the DNA. The cell then tries to repair these breaks, but errors can occur during the repair process, resulting in changes in the DNA sequence.

3.2.3 Frontier Progress:

In recent years, gene editing technology has made important progress in many fields. In scientific research, gene editing allows researchers to study the functions and interactions of genes more accurately. In the medical field, gene editing technology provides new possibilities for treating genetic diseases and cancer. In addition, gene editing is also widely used in agriculture and biotechnology to improve crops and increase production efficiency.

3.2.4 Application in scientific research and medical treatment:

In scientific research, gene editing technology is widely used in gene function research, disease model establishment, and drug screening. In the medical field, gene editing technology provides a potential treatment for genetic diseases and cancer. For example, gene editing technology can repair or replace disease-causing genes, thereby curing or alleviating certain genetic diseases. In addition, gene editing technology can also be used to create personalized drugs and treatment plans to meet the personalized needs of patients.

GenBook 's gene editing technology has brought tremendous changes and possibilities to the fields of scientific research and medicine. By precisely modifying the genome of an organism, researchers can gain a deeper understanding of the mysteries of life and develop new treatments.

However, this technology also faces ethical, safety and technical challenges that need to be considered and addressed in future research and applications.

3.3 Combination of blockchain technology and gene editing technology

3.3.1 Significance and advantages of combination:
Combining GenBook ’s blockchain technology with gene editing technology can bring unprecedented changes and advantages to the biotechnology field. This combination means that we can use the decentralized, transparent and tamper-proof characteristics of blockchain technology to ensure the security, integrity and credibility of gene editing data.

3.3.2 Data Sharing and Cooperation:
Through blockchain technology, researchers, medical institutions, biotechnology companies, etc. can more easily share and collaborate on gene editing data. These data will be permanently and securely stored on the blockchain to ensure that the data will not be tampered with or lost. At the same time, due to the transparency of the blockchain, all participants can verify the source and authenticity of the data, thereby establishing a trust mechanism.

3.3.3 Privacy Protection and Ethical Review:
Gene editing involves personal privacy and ethical issues. Through blockchain technology, we can achieve data anonymity and privacy protection to ensure that personal genetic information is not leaked. At the same time, we can also use smart contracts to automate the ethical review process to ensure that gene editing research complies with ethical standards and laws and regulations.

3.3.4 Promote innovation and application:
Combining blockchain technology with gene editing technology can accelerate the transformation and application of scientific research results. By building a safe, transparent and efficient data sharing and cooperation platform, we can attract more researchers and enterprises to participate in gene editing research, thereby promoting technological innovation and development.

GenBook 's blockchain technology and gene editing technology will bring revolutionary changes to the field of biotechnology. By ensuring the security, integrity and credibility of data, promoting data sharing and cooperation, and accelerating the transformation and application of scientific research results, this combination is expected to promote the rapid development and widespread application of gene editing technology.

4. Token Economic Model

4.1 Token Distribution Model

Token Name: GEBT
Total Tokens: 300 million

IDO: 1 5%
Technology: 10%
Operation: 10%
Foundation: 15%
Mining: 50 %



4.2 Characteristics of GEBT economic model

4.2.1 Community and User Participation Orientation

A distinctive feature of the GEBT token economic model is its strong emphasis on community and user participation. Up to 50% of the tokens are allocated for mining and incentive mechanisms, which ensures that users can obtain token rewards by participating in platform activities, contributing content, completing tasks, etc. This strategy not only helps attract a large number of users to join the platform ecosystem, but also stimulates user enthusiasm and participation, and promotes the activity and healthy development of the community.

4.2.2 Rationality of resource allocation

In the GEBT token economic model, the allocation of resources is carefully planned and considered. In addition to allocating 10% of tokens for technology research and development to ensure that the core technology and functions of the project can be continuously iterated and optimized, corresponding tokens are also reserved for marketing, community operations, and partnership building. This balanced resource allocation strategy contributes to the overall development of the project, ensuring that all key areas receive adequate support and attention.

4.2.3 Balancing short-term and long-term development

This model not only focuses on the short-term development of the project, but also takes into account long-term sustainability. Through the IDO (Initial DEX Offering) mechanism, the project can attract a group of investors in the early stage to provide the necessary liquidity for the project. At the same time, the establishment of the foundation and mining mechanism provides financial guarantee and continuous motivation for the long-term development of the project. This strategy ensures that the project can get started quickly in the short term and maintain steady growth and development in the long term.

GEBT token economic model are that it focuses on community and user participation, rationally allocates resources, and takes into account both short-term and long-term development. These characteristics enable the model to attract and retain users, promote community activity and healthy development, and ensure the comprehensive and sustainable development of the project.

4.3 Application Scenarios

4.3.1 Payment of trading platform fees:

On GenBook 's trading platform, users can use GEBT tokens to pay transaction fees. These fees include but are not limited to buying and selling gene editing data, participating in auctions, using advanced search functions, etc. Using GEBT tokens to pay can provide users with a more convenient and economical trading experience.

4.3.2 Incentive and Reward Mechanism:

GEBT tokens play an important role in the GenBook ecosystem. Users can obtain GEBT token rewards by participating in community building, contributing content, completing tasks, etc. These rewards can motivate users and promote the activity and healthy development of the community.

4.3.3 Access and use of advanced features:

On the GenBook platform, some advanced features or services may require users to pay GEBT tokens to access or use. These advanced features may include more detailed gene editing data analysis, customized research tools, priority participation in certain projects or activities, etc.

4.3.4 Partners and Ecosystem Co-construction:

GEBT tokens can also be used for cooperation and co-construction between partner companies or research institutions that cooperate with GenBook . For example, partners can use GEBT tokens to pay for services, participate in project cooperation, share resources, etc. This form of cooperation helps expand the GenBook ecosystem and promote the common development of the ecosystem.

4.3.5 Governance and Voting:

In GenBook 's community governance, GEBT token holders can participate in community decision-making through voting. Holders can use tokens to vote on proposals to express their opinions and preferences. This governance mechanism helps ensure fairness and transparency in the community and promotes the long-term development of the community.

5.Team Introduction

5.1 Core Team

GenBook team has brought together many outstanding talents, with strong technical strength and rich industry experience. We firmly believe that through the joint efforts and continuous innovation of the team, GenBook will become the world's leading genetic data trading and sharing platform, making important contributions to the development of the biotechnology field.

Mike Allen ： CEO

Mike Allen is an outstanding leader with extensive experience and deep background in the biotechnology and blockchain fields. Under his leadership, GenBook has achieved significant results. He led the team to successfully develop blockchain technology with independent intellectual property rights and combined it with gene editing technology, bringing innovative solutions to the global biotechnology field.

Thomas Bauer ： CTO

Thomas has more than ten years of experience in the R&D and application of blockchain technology, and has served as core development roles in several well-known blockchain projects. He has in-depth understanding and practical experience in blockchain security, scalability and smart contract design. Before joining GenBook , Thomas was the chief architect of a top blockchain company, responsible for the design and implementation of multiple high-performance, high-security blockchain solutions.

Jacob Boxhoorn : COO

Jacob has held senior management positions in several well-known technology companies and has more than ten years of operations and marketing experience. He is good at developing and executing strategic plans, proficient in team management and resource allocation, and can remain efficient and sharp in a fast-paced and ever-changing environment. Before joining GenBook , Jacob served as COO at a leading biotech company and successfully led the company's market expansion and operational optimization. He has a deep understanding of market trends and customer needs in the biotech industry and can translate these insights into effective business strategies.

5.2 Advisory Team

GenBook 's advisory team is composed of a group of experts with profound attainments in the fields of biotechnology, blockchain technology, healthcare, and financial investment. They provide GenBook with valuable strategic guidance, technical consulting, and resource docking, helping the project maintain its leading position in the complex and ever-changing industry environment.

Dr. Elizabeth Thompson : Consultant in the biotechnology field

Dr. Elizabeth Thompson is an internationally renowned biotechnology expert with more than 20 years of experience in genomics research and development. She has worked as a senior scientist at the world's top biotechnology companies and has achieved breakthrough results in multiple biotechnology projects. Dr. Thompson has a deep understanding of the potential and challenges of gene editing technology and has provided GenBook with valuable technical guidance and industry insights.

Prof. Mark Johnson : Blockchain Technology Consultant

Prof. Mark Johnson is a well-known scholar and expert in the blockchain field with more than 10 years of experience in blockchain research and development. He has participated in the development of many well-known blockchain projects and published academic papers on blockchain technology at many international conferences. Prof. Johnson provides strategic planning and technical support for blockchain technology for GenBook , ensuring that the platform reaches industry-leading levels in terms of security, scalability, and smart contract design.

Dr. Robert Davis : Consultant in the healthcare field

Dr. Robert Davis is an expert with extensive experience in the healthcare field, and has held senior management positions in world-renowned medical institutions and biotech companies. He has a deep understanding of the application of genetic data in the healthcare field and provided GenBook with valuable advice on how to meet industry needs and compliance requirements.

Mr. Steven Wu : Financial investment consultant

Mr. Steven Wu is a senior financial investment expert with more than 15 years of investment experience and a deep financial background. He has held senior positions in several well-known investment institutions and participated in many successful investment projects. Mr. Wu provided guidance on fund raising, investment strategy and market analysis for GenBook , helping the project to succeed in the capital market.

These consultants have rich experience and deep expertise in their respective fields, and their joining provides strong support for GenBook . Through close cooperation with the consultant team, GenBook can better respond to industry challenges and achieve continuous innovation and long-term development.

6. Project development route

Short-term goals (1-2 years)

Technology R&D and platform building

* Improve the underlying blockchain technology to ensure the security, stability and scalability of the platform.
* Develop smart contracts to enable transparent and verifiable transactions of genetic data.
* Build a user-friendly interface and interactive experience to lower the threshold for use.

Team Building and Expansion

* Recruit more outstanding talents to strengthen the technology research and development, marketing, operation management and other teams.
* Establish a sound training mechanism to enhance the overall capabilities of the team.

Marketing and Cooperation

* Conduct market research within the industry to identify target customer groups and market demands.
* Develop and implement marketing strategies to increase brand awareness and market share.
* Establish cooperative relationships with biotechnology companies, medical institutions, scientific research institutions, etc. to expand application scenarios.

Medium-term goals (3-5 years)

Product optimization and upgrade

* Continuously optimize platform functions and user experience based on market feedback and user needs.
* Introduce more innovative technologies, such as artificial intelligence, big data analysis, etc., to enhance the value of the platform.

Expanding global markets

* Analyze global market demand and competition situation and formulate international development strategy.
* Strengthen communication and cooperation with international partners to promote the application of projects on a global scale.

Building an Ecosystem

* Attract more developers, research institutions and enterprises to join and jointly build a prosperous ecosystem.
* Provide rich development tools and support to lower the threshold for developers and promote the development of innovative applications.

Long-term goals (more than 5 years)

Technology Leadership

* Maintain a leading position in the field of blockchain and gene editing technology and lead the direction of industry development.
* Continue to invest in research and development, explore more cutting-edge technologies, and provide strong support for the long-term development of the platform.

Deepening industrial integration

* Integrate deeply with more industrial fields to expand the application scenarios and scope of genetic data.
* Promote cross-border cooperation in biotechnology, financial technology, medical health and other fields to promote industrial innovation.

Social Responsibility and Sustainable Development

* Pay attention to social and environmental issues and actively fulfill corporate social responsibilities.
* Promote the compliant use and protection of genetic data and maintain user privacy and data security.
* Promote the sustainable development of biotechnology and contribute to the health and well-being of all mankind.

Through this project development roadmap, GenBook will advance the project development in a phased and planned manner to ensure that the expected results can be achieved at each stage. At the same time, the team will flexibly adjust according to market changes and industry needs to adapt to the ever-changing market environment.

7. Disclaimer

Nothing in this white paper constitutes legal, financial, business or tax advice, and you should consult your own legal, financial, business or other professional advisors before participating in any activities related to this. Platform staff, project development team members, third-party development organizations and service providers are not responsible for any direct or indirect damages and losses that may result from the use of this white paper.

This white paper is for general information purposes only and does not constitute a prospectus, an offer document, an offer of securities, a solicitation for investment, or any offer to sell any product, item, or asset (whether digital or other assets). The following information may not be exhaustive and does not imply any elements related to a contract. The white paper cannot guarantee the accuracy or completeness of the information, and does not guarantee or promise to provide an explanation of the accuracy and completeness of the information. In the event that this white paper contains information obtained from a third party, the platform and the team have not independently verified the accuracy and completeness of such information. In addition, you need to understand that the surrounding environment and circumstances may change at any time, so this white paper may become outdated as a result, and the platform has no obligation to update or correct the content and documents related thereto.

No part of this white paper constitutes and will not constitute any offer by the platform, distributors and any sales team (as defined in this Agreement), nor can the contents stated in the white paper be used as the basis for any contract and investment decision. Nothing contained in this white paper can be used as a statement, promise or guarantee of future performance. By accessing and using this white paper or any content therein, you will provide the following guarantees to the platform, its affiliates and your team:

◎ In any decision to purchase assets (GEBT tokens), you have not relied on any statement in this white paper;

◎ You will voluntarily bear the costs and ensure compliance with all laws, regulatory requirements and restrictions applicable to you (as the case may be);

◎ You acknowledge, understand and agree that the assets may have no value, are not guaranteed or represent any value and circulation properties, and cannot be used for speculative investment;

◎ The platform, its affiliates and team members are not responsible or liable for the value, transferability, liquidity of assets, or any market for the GenBook project provided by third parties or otherwise;

◎ You acknowledge, understand and agree that you will not be eligible to purchase any Assets if you are a citizen, national, resident (tax or other related), green card holder of a geographic region or country that meets the following conditions:

- sales of assets that could be defined or construed as sales of securities (however designated) or investments;

• Countries and regions where it is prohibited by law to contact and participate in the sale of assets or where assets are prohibited by laws, policies, regulations, treaties or administrative regulations.

The platform and the team will not and do not intend to make any representations, warranties or promises to any entity or individual, and hereby declare that they do not assume any responsibility (including but not limited to the accuracy, completeness, timeliness and reliability of the content of this white paper and any other materials published by the platform). To the maximum extent permitted by law, the platform, related entities and service providers shall not be liable for any indirect, special, incidental, indirect or other forms of loss caused by infringement, contract disputes or other forms of use (including but not limited to any liability caused by breach of contract or negligence, any loss of income and profit, and loss of use and data) arising from the use of the content of the white paper, the relevant materials published by the platform and the relevant content displayed in other forms (including but not limited to any errors or omissions). Potential buyers should carefully consider and evaluate all risks and uncertainties (including financial, legal and uncertain risks) associated with sales, platforms, distributors and teams.

The information provided in this white paper is for community discussion only and is not legally binding. No one is obliged to enter into any contract and binding legal commitment to acquire GenBook, and this white paper will not accept any virtual currency or other forms of payment. The purchase and sale agreement of assets and the long-term continuous holding of assets are subject to a set of independent terms or a purchase agreement containing relevant terms and conditions (as the case may be), which will be provided to you separately or can be obtained from the website. If there is any inconsistency between these terms and conditions and this white paper, these terms and conditions shall prevail. No regulatory authority has reviewed or approved any information set out in this white paper, and there is no provision in the laws, regulatory requirements and rules of any jurisdiction that requires or will require this. The publication, distribution or dissemination of this white paper does not mean that the applicable laws, regulatory requirements or rules have been fulfilled and complied with.

This is just a conceptual white paper to describe the long-term development goals of the GenBook project to be developed. This white paper may be modified or replaced from time to time. There is no obligation to update the white paper and provide the audience with other information beyond the scope of this white paper. All statements contained in the white paper, press releases and publicly accessible statements, as well as oral statements that may be made by the platform and the GenBook project team, may constitute forward-looking statements (including related statements of intent and confidence and expectations regarding current market conditions, business strategies and plans, financial conditions, specific regulations and risk management decisions).

Please note that you should not place undue reliance on these forward-looking statements, as these statements involve known and unknown risks, uncertainties and other factors, which may cause actual future results to be materially different from those described in these forward-looking statements. At the same time, it should be noted that no independent third party has reviewed and judged the rationality of these statements and assumptions. These forward-looking statements apply only to the date indicated in this white paper, and the platform and the GenBook project team expressly disclaim any responsibility (whether express or implied) for the consequences or events caused and generated by the revision of these forward-looking statements after that date.

The names or trademarks of any companies or platforms used herein (except those related to the platform or its affiliates) do not imply any association with or endorsement by these third-party platforms and companies. Specific companies and platforms mentioned in this white paper are for reference and illustration purposes only.